News

Firm Rx roots help big-box make its ‘Marc’

BY Barbara White-Sax

Twenty years ago, big-box drug chains selling everything but the kitchen sink were a popular format. Most of those chains are gone, but Cleveland-based Marc Glassman has not only has managed to hang on, but also continues to grow.

The large-format stores known for their sharp pricing and deal purchases continue to carry a variety of merchandise from liquidations, overstocks, closeouts and buybacks, and customers seem to love the fact that they never know what they might find when they shop the chain.

Marc’s operates 65 stores—60 Marc’s locations in northeast Ohio and five Xpect Deep Discount Drug Stores in Connecticut. Opportunistic buying makes the chain strong in general and seasonal merchandise, but the chain still is firmly rooted in pharmacy.

Discount positioning is evident in the pharmacy department as well, where the chain promotes generic drugs. For several years, Marc’s has offered $3.99 for a 30-day supply and $9.99 for a 90-day supply deals on more than 400 generic drugs.

Marc’s isn’t just about price, and the chain aims to offer its customers “outstanding services, efficient operations and innovative business solutions.” In the pharmacy department, Marc’s automated prescription line allows consumers to not only connect with a pharmacy associate, but also determine what time their prescriptions will be ready to pick up.

The chain has continued to expand its grocery departments. It partners with key growers and employs a strategy of high product volume and multiple inventory turns. Daily product management enables Marc’s to bring consumers a full line of fresh seasonal and everyday fruits. Marc’s also offers a gourmet cheese section at many of its locations, and has added meat at nearly 50 stores. The chain also has begun to tell customers about its best food deals on Twitter.

MARC GLASSMAN

Headquarters: Cleveland2009 sales: $1.0 billion% change vs. 2008: 8%No. of stores: 65No. of stores with Rx: 52Avg. store size: 50,000 sq. ft.Rx sales: $150 million% of sales from Rx: 15%Sales per store: $15.4 millionSource: Drug Store News

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
News

Schnucks’ O’Brien to serve on Department of Agriculture advisory committee

BY Alaric DeArment

ST. LOUIS An executive from Schnuck Markets will serve on an advisory committee of the Department of Agriculture, Schnucks said this week.

Agriculture secretary Tom Vilsack announced that Schnucks VP produce and floral Mike O’Brien would be one of 25 people appointed to a two-year term on the USDA’s Fruit and Vegetable Industry Advisory Committee. O’Brien is also vice chairman of the Produce Marketing Association.

 

“I am honred to represent Schnuck Markets and the retail produce industry as a member of this committee,” O’Brien said. “I am looking forward to the opportunity to contribute and to make a difference for families across the nation.”

The committee, originally chartered in 2001, advises the secretary of agriculture on industry issues related to fruits and vegetables.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
News

Gilead commences phase 3 trial for single-tablet HIV treatment

BY Alaric DeArment

FOSTER CITY, Calif. Gilead Sciences has started a late-stage clinical trial of an investigational 4-in-1 treatment for HIV, the drug maker said.

Gilead announced the initiation of a phase 3 trial of its “Quad” HIV drug, a single-tablet treatment that combines elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate. The study will compare the Quad regimen with the standard of care among adults with HIV-1 who have not taken antiretroviral treatments. The company is also investigating cobicistat as a standalone boosting agent for antiretroviral drugs.

“We are pleased to announce that the Quad phase 3 clinical program is underway,” Gilead EVP research and development and chief scientific officer Norbert Bischofberger said. “Efficacy and safety results from the phase 2 study suggest that the Quad may represent an important new option for patients with HIV.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?